Early sCD8 plasma levels during subcutaneous rIl-2 therapy in patients with renal cell carcinoma correlate with response.
Plasma sIl-2R and sCD8 levels of 12 patients with renal cell carcinoma were determined before and during subcutaneous rIl-2 therapy. Patients with a complete/partial remission showed a significantly stronger initial increase of sCD8 compared to patients with stable disease or tumour progression.
Martens
A
A
Department of Clinical Immunology, University Hospital Groningen, The Netherlands.
Janssen
R A
RA
Sleijfer
D T
DT
Heijn
A A
AA
Mulder
N H
NH
The
T H
TH
de Leij
L
L
D000328:Adult; D000368:Aged; D016827:CD8 Antigens / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use; D012995:Solubility; D013997:Time Factors
D016827:CD8 Antigens; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins